DOP2013000043A - Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos - Google Patents

Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos

Info

Publication number
DOP2013000043A
DOP2013000043A DO2013000043A DO2013000043A DOP2013000043A DO P2013000043 A DOP2013000043 A DO P2013000043A DO 2013000043 A DO2013000043 A DO 2013000043A DO 2013000043 A DO2013000043 A DO 2013000043A DO P2013000043 A DOP2013000043 A DO P2013000043A
Authority
DO
Dominican Republic
Prior art keywords
cells
compositions
methods
lymphatic
progenitating
Prior art date
Application number
DO2013000043A
Other languages
English (en)
Inventor
Theresa Deisher
Original Assignee
Theresa Deisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theresa Deisher filed Critical Theresa Deisher
Publication of DOP2013000043A publication Critical patent/DOP2013000043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para inhibir la unión de células madre a órganos y tejidos, que incluye el bloqueo de la unión de células madre a centros germinales presentes en el tejido linfático. Se describen composiciones y métodos para regenerar los centros germinales en el tejido linfático. En las composiciones se incluyen adyuvantes, agonistas del receptor de CD40, CD28 y IL-21 y antagonista de CD20. .
DO2013000043A 2010-08-18 2013-02-14 Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos DOP2013000043A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37494310P 2010-08-18 2010-08-18
US201161441485P 2011-02-10 2011-02-10
US201161449372P 2011-03-04 2011-03-04

Publications (1)

Publication Number Publication Date
DOP2013000043A true DOP2013000043A (es) 2013-09-30

Family

ID=45594254

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000043A DOP2013000043A (es) 2010-08-18 2013-02-14 Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos

Country Status (19)

Country Link
US (2) US20120045435A1 (es)
EP (2) EP3530274A1 (es)
JP (3) JP6096116B2 (es)
KR (3) KR101833204B1 (es)
CN (1) CN103167870B (es)
AU (1) AU2011291651B2 (es)
BR (1) BR112013003169B1 (es)
CA (1) CA2844109C (es)
CR (1) CR20130117A (es)
DO (1) DOP2013000043A (es)
ES (1) ES2738115T3 (es)
IL (1) IL224727B (es)
MX (1) MX368272B (es)
MY (1) MY179491A (es)
NZ (1) NZ607906A (es)
RU (1) RU2645069C2 (es)
SG (2) SG187840A1 (es)
WO (1) WO2012024519A2 (es)
ZA (2) ZA201301800B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US20170216434A1 (en) * 2014-08-05 2017-08-03 Wayne State University Compositions and methods for treatment of sickle cell disease
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
US20180353472A1 (en) * 2015-11-09 2018-12-13 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
CN107034272B (zh) * 2016-12-14 2020-09-29 河北医科大学第四医院（河北省肿瘤医院） Cxcl2在制备诊断或治疗肺腺癌工具中的应用
CA3054443A1 (en) * 2017-04-01 2018-10-14 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3639855A4 (en) * 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
AU2018283250B2 (en) 2017-06-16 2022-09-01 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
BR112020010662A2 (pt) * 2017-11-29 2020-11-10 Magenta Therapeutics, Inc. composições e métodos para a depleção de células cd5+
RU2707281C1 (ru) * 2018-09-17 2019-11-26 Гордейчук Владимир Евгеньевич Способ иммунотерапии раковых заболеваний
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
SG11202104084WA (en) * 2018-10-30 2021-05-28 Magenta Therapeutics Inc Methods for allogeneic hematopoietic stem cell transplantation
JP7337060B2 (ja) 2018-11-14 2023-09-01 エーブイエム・バイオテクノロジー・エルエルシー 安定なグルココルチコイド製剤
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
WO2021211450A1 (en) * 2020-04-13 2021-10-21 Fred Hutchinson Cancer Research Center Conditioning regimens for in vivo gene therapy
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
KR102285160B1 (ko) * 2020-12-24 2021-08-03 주식회사 타임바이오 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
GB9323199D0 (en) * 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20030138429A1 (en) * 2001-05-22 2003-07-24 Pizzo Salvatore V. Compositions and methods for inhibiting metastasis
IL146970A0 (en) * 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
EP2272512A1 (en) * 2002-05-17 2011-01-12 Celgene Corporation Pharmaceutical compositions for treating cancer
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
PT1835924E (pt) * 2004-12-23 2013-11-19 Ethicon Inc Tratamento da doença de parkinson e desordens relacionadas usando células derivadas do pós-parto
US20080138415A1 (en) * 2006-09-26 2008-06-12 Mehboob Hussain Composition and method for producing composition for constructing tissue, and tissue construct
MX2009004776A (es) 2006-11-03 2009-07-14 Multiple Sclerosis Res Ct Of N Celulas madre mesenquimaticas derivadas de medula osea como una fuente de progenitores neurales.
US20100247491A1 (en) * 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
EP2131863A4 (en) * 2007-03-14 2012-07-11 Univ Tokyo PROCESS FOR TREATING MALLED MESOTHELIOMA
JP4743215B2 (ja) 2008-02-07 2011-08-10 株式会社ジェイ・エム・エス 血液透析装置
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2010006261A1 (en) 2008-07-10 2010-01-14 Hong John J Methods for inducing stem cell migration and specialization with ec-18

Also Published As

Publication number Publication date
KR20190017065A (ko) 2019-02-19
US20120045435A1 (en) 2012-02-23
US9962408B2 (en) 2018-05-08
CA2844109A1 (en) 2012-02-23
JP6437988B2 (ja) 2018-12-12
AU2011291651A1 (en) 2013-03-21
CR20130117A (es) 2013-05-31
EP2605765A2 (en) 2013-06-26
JP2014501694A (ja) 2014-01-23
WO2012024519A3 (en) 2012-04-19
MX2013001835A (es) 2013-02-26
JP2017081948A (ja) 2017-05-18
SG187840A1 (en) 2013-03-28
EP3530274A1 (en) 2019-08-28
BR112013003169B1 (pt) 2022-05-24
KR20180023040A (ko) 2018-03-06
JP2019059744A (ja) 2019-04-18
WO2012024519A2 (en) 2012-02-23
US20170128493A1 (en) 2017-05-11
NZ607906A (en) 2015-11-27
EP2605765B1 (en) 2019-05-08
WO2012024519A4 (en) 2012-06-28
CN103167870A (zh) 2013-06-19
JP6096116B2 (ja) 2017-03-15
ZA201402419B (en) 2015-12-23
SG10201600621VA (en) 2016-02-26
KR102173938B1 (ko) 2020-11-04
RU2645069C2 (ru) 2018-02-15
IL224727B (en) 2018-02-28
BR112013003169A2 (pt) 2016-06-28
AU2011291651B2 (en) 2016-01-14
RU2013110492A (ru) 2014-09-27
JP6716668B2 (ja) 2020-07-01
MX368272B (es) 2019-09-26
CA2844109C (en) 2018-11-06
KR101833204B1 (ko) 2018-03-02
MY179491A (en) 2020-11-08
ZA201301800B (en) 2014-07-30
ES2738115T3 (es) 2020-01-20
CN103167870B (zh) 2018-11-16
KR20140027901A (ko) 2014-03-07

Similar Documents

Publication Publication Date Title
DOP2013000043A (es) Composiciones y métodos para inhibir la unión de células madre y células progenitoras a tejido linfoide y para regenerar centros germinales en tejidos linfáticos
DOP2019000030A (es) Inhibidores de cdk2/4/6
DOP2014000204A (es) Compuestos de heterociclilo como inhibidores de mek
AR091837A1 (es) Compuestos para inmunoterapia dirigida
GT201400187A (es) Derivados macrocíclicos para el tratamiento de enfermedades
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
ECSP14004976A (es) Anticuerpos anti-il-36r
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
CR20140312A (es) 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201400133A (es) Inhibidores de bromodominios
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
ECSP14013215A (es) Compuestos novedosos
BR112013022042A2 (pt) tecido não tecido contendo material de prótese óssea
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
CR20150171A (es) Benzamidas
ECSP13013012A (es) Análogos del ácido epoxieicosatrienoicos y métodos de preparación
DOP2013000304A (es) Moduladores alostéricos positivos del receptor de acetilcolina nicotínico
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas